PRO DEX INC - 10-Q Filing Summary
Business Context and Reporting Period
Company: PRO DEX INC (PDEX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2025 (Fiscal Q2 2026)
Business Overview: Pro-Dex designs, develops, and manufactures autoclavable, battery-powered, and electric surgical drivers and shavers for orthopedic, thoracic, and maxocranial facial markets. The company also provides engineering and regulatory consulting services.
Key Financial Metrics
| Metric (in thousands) | 3 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2025 | 6 Months Ended Dec 31, 2024 |
|---|---|---|---|
| Net Sales | $18,663 | $37,194 | $31,686 |
| Gross Profit | $5,743 | $11,111 | $10,222 |
| Gross Margin | 31% | 30% | 32% |
| Operating Income | $3,259 | $6,368 | $5,705 |
| Net Income | $2,187 | $6,867 | $4,506 |
| Diluted EPS | $0.66 | $2.07 | $1.33 |
| Cash & Equivalents (End of Period) | $7,953 (Dec 31, 2025) | ||
| Total Debt (Notes Payable) | $10,507 (Dec 31, 2025) | ||
| Working Capital | $36,985 (Dec 31, 2025) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 11% ($1.9M) for the quarter and 17% ($5.5M) for the six-month period compared to the prior year. Orthopedic sales drove growth, up 27% (quarter) and 43% (six months), attributed to the launch of a next-generation handpiece for the largest customer.
- Investment Gain: Net income was significantly boosted by a $6.8 million realized gain from the sale of Monogram Technologies, Inc. shares following its acquisition by Zimmer Biomet. This gain was offset in the quarter by the reversal of a previously recorded unrealized gain, resulting in a net impact primarily visible in the six-month period.
- Repair Revenue Decline: Repair revenue decreased 35% (quarter) and 30% (six months) due to fewer repairs of legacy orthopedic handpieces as customers transition to newer models.
- Operating Expenses: General and administrative expenses increased 23% (quarter) and 19% (six months), driven by a $225,000 CEO bonus and consulting fees related to a potential supplier acquisition. R&D costs decreased 22% (quarter) and 16% (six months) due to lower recruiting and legal fees.
- Liquidity: Cash and cash equivalents surged from $419,000 at June 30, 2025, to $7,953,000 at December 31, 2025, primarily due to proceeds from the Monogram investment sale.
Guidance, Outlook, and Risks
- Backlog: As of December 31, 2025, the company reported a backlog of approximately $37.4 million, with $32.5 million scheduled for delivery in fiscal 2026.
- Strategic Initiatives: Management is actively pursuing the acquisition of a significant supplier to meet increased demand. The company expects to release the "Helios" driver for CMF applications later in the fiscal year.
- Customer Concentration: The company faces high customer concentration risk. Customer 1 accounted for 79% of sales in both the three and six-month periods ended December 31, 2025. Customer 1 also represented 82% of gross accounts receivable.
- Debt Covenants: The company is in compliance with debt covenants as of December 31, 2025, but notes there is no assurance of future compliance. Total notes payable include term loans and a revolving credit facility with UMB Bank.
- Contingent Value Rights (CVRs): The company holds CVRs from the Monogram transaction valued up to $12.37 million if specific milestones are met, though there is no guarantee these will be achieved.
Key Facts for Investor Verification
- Revenue Concentration: Verify the stability of the relationship with the single customer representing 79% of total sales and 82% of accounts receivable.
- Non-Recurring Gains: Assess the sustainability of earnings by excluding the $6.8 million one-time gain from the Monogram investment sale.
- Repair Revenue Trend: Monitor the continued decline in repair revenue as legacy products are replaced, and its impact on overall gross margins.
- Supplier Acquisition: Track progress on the potential acquisition of a key supplier mentioned in management commentary.
- Debt Structure: Review the maturity dates of outstanding term loans (ranging from 2027 to 2030) and the utilization of the $11 million revolving credit facility.